Tevogen Bio Holdings Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021
Period Ending	Sep '24 Sep 30, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Selling, General & Admin	17.99	5.32	8.43	1.66
Research & Development	28.22	3.52	5.29	2.96
Operating Expenses	46.21	8.84	13.72	4.62
Operating Income	-46.21	-8.84	-13.72	-4.62
Interest Expense	-0.49	-1.21	-0.93	-0.6
Interest & Investment Income	0	0	0	0
EBT Excluding Unusual Items	-47.58	-10.05	-14.66	-5.22
Other Unusual Items	47.16	-50.43	-7.38	-10.38
Pretax Income	-7.92	-60.48	-22.04	-15.6
Net Income	-7.92	-60.48	-22.04	-15.6
Net Income to Common	-4.5	-60.48	-22.04	-15.6
Shares Outstanding (Basic)	126	25	25	25
Shares Outstanding (Diluted)	126	25	25	25
Shares Change (YoY)	409.77%	-1.98%	0.69%	-
EPS (Basic)	-0.04	-2.44	-0.87	-0.62
EPS (Diluted)	-0.04	-2.44	-0.87	-0.62
Free Cash Flow	-10.93	-8.3	-9.13	-5.38
Free Cash Flow Per Share	-0.09	-0.34	-0.36	-0.21
EBITDA	-46.04	-8.68	-13.63	-4.61
D&A For EBITDA	0.17	0.16	0.09	0.01
EBIT	-46.21	-8.84	-13.72	-4.62

Updated Nov 19, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q